MX2022016403A - Formulaciones de anticuerpo de activina a y métodos para utilizarlas. - Google Patents

Formulaciones de anticuerpo de activina a y métodos para utilizarlas.

Info

Publication number
MX2022016403A
MX2022016403A MX2022016403A MX2022016403A MX2022016403A MX 2022016403 A MX2022016403 A MX 2022016403A MX 2022016403 A MX2022016403 A MX 2022016403A MX 2022016403 A MX2022016403 A MX 2022016403A MX 2022016403 A MX2022016403 A MX 2022016403A
Authority
MX
Mexico
Prior art keywords
activin
antibody
methods
antibody formulations
formulations
Prior art date
Application number
MX2022016403A
Other languages
English (en)
Spanish (es)
Inventor
Douglas Kamen
Kenneth Graham
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2022016403A publication Critical patent/MX2022016403A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MX2022016403A 2020-06-18 2021-06-18 Formulaciones de anticuerpo de activina a y métodos para utilizarlas. MX2022016403A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063040589P 2020-06-18 2020-06-18
PCT/US2021/038016 WO2021257947A1 (en) 2020-06-18 2021-06-18 Activin a antibody formulations and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022016403A true MX2022016403A (es) 2023-04-11

Family

ID=77168377

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016403A MX2022016403A (es) 2020-06-18 2021-06-18 Formulaciones de anticuerpo de activina a y métodos para utilizarlas.

Country Status (13)

Country Link
US (1) US12472253B2 (enExample)
EP (1) EP4168038A1 (enExample)
JP (2) JP7850084B2 (enExample)
KR (1) KR20230026407A (enExample)
CN (1) CN116322768A (enExample)
AU (1) AU2021293577A1 (enExample)
BR (1) BR112022025700A2 (enExample)
CA (1) CA3183316A1 (enExample)
CL (1) CL2022003586A1 (enExample)
CO (1) CO2023000264A2 (enExample)
IL (1) IL299103A (enExample)
MX (1) MX2022016403A (enExample)
WO (1) WO2021257947A1 (enExample)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
US20160075772A1 (en) * 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
US20180008672A1 (en) * 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
CN109641954A (zh) 2016-08-29 2019-04-16 里珍纳龙药品有限公司 抗-gremlin-1(grem1)抗体及其用于治疗肺动脉高血压的使用方法
WO2018184692A1 (en) * 2017-04-07 2018-10-11 Ares Trading S.A. Liquid pharmaceutical composition
MX2020004756A (es) * 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
IL276921B2 (en) * 2018-03-01 2025-12-01 Regeneron Pharma Methods for altering body composition

Also Published As

Publication number Publication date
BR112022025700A2 (pt) 2023-02-28
AU2021293577A1 (en) 2023-02-09
JP2026108880A (ja) 2026-06-30
EP4168038A1 (en) 2023-04-26
KR20230026407A (ko) 2023-02-24
CL2022003586A1 (es) 2023-07-21
CA3183316A1 (en) 2021-12-23
IL299103A (en) 2023-02-01
US20210393779A1 (en) 2021-12-23
WO2021257947A1 (en) 2021-12-23
CO2023000264A2 (es) 2023-01-26
CN116322768A (zh) 2023-06-23
JP7850084B2 (ja) 2026-04-22
JP2023532203A (ja) 2023-07-27
US12472253B2 (en) 2025-11-18

Similar Documents

Publication Publication Date Title
CY1123909T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r)
PH12019502123A1 (en) Stable antibody formulation
CL2019003032A1 (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas.
SA519401317B1 (ar) تركيبات أو مستحضرات لقاح المكورات الرئوية متعددة التكافؤ والتي تضم اتحادات البروتين مع عديد السكاريد
CY1121233T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα καtα του υποδοχεα iντερλευκinης-4(ιl-4r)
BR112021026414A2 (pt) Formulação compreendendo o anticorpo biespecífico anti-cd47/pd-l1, método para preparo e uso do mesmo
MA56289A (fr) Mutéines d'interleukine-21 et méthodes de traitement
PH12021552092A1 (en) Stabilized formulations containing anti-il-33 antibodies
EP4374851A3 (en) Ophthalmic composition for treatment of dry eye disease
JO3533B1 (ar) تركيبات ثابته تحتوي على مضادات حيوية مقاومة لـ ang2
MX2023009971A (es) Composicion farmaceutica que contiene anticuerpo anti-tslp.
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
MX2022015734A (es) Proteinas de exotoxina a modificadas.
PH12014502429A1 (en) Stabilized formulations containing anti-dll4 antibodies
MX2022008949A (es) Formulacion de anticuerpos estable.
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
MY209656A (en) Compositions and methods of enhancing 5-hydroxytryptophan bioavailability
SA520420261B1 (ar) تركيبات إرنوماب واستخداماتها
EP4412643A4 (en) COMPOSITIONS AND METHODS FOR REDUCING THE ADVERSE EFFECTS OF STORAGE, TRANSPORTATION, AND ADMINISTRATION OF ANTIGEN-CONTAINING FORMULATIONS
MX2022014455A (es) Formulacion de anticuerpo anti-clever-1 estable.
CO2023000264A2 (es) Formulaciones de anticuerpo de activina a y métodos para utilizarlas
EA201992142A1 (ru) Фармацевтические композиции и их применения
EP4238577A3 (en) Compositions for administration of different doses of rna
BR112022002094A2 (pt) Composição imunogênica
BR112021026409A2 (pt) Formulação compreendendo o anticorpo anti-lag-3, método para preparo e uso do mesmo